Home » Stocks » MRNA

Moderna, Inc. (MRNA)

Stock Price: $131.02 USD -1.96 (-1.47%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Pre-market: $131.63 +0.61 (0.47%) Jan 25, 5:11 AM
Market Cap 51.85B
Revenue (ttm) 246.71M
Net Income (ttm) -597.70M
Shares Out 394.68M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE 48.54
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $131.02
Previous Close $132.98
Change ($) -1.96
Change (%) -1.47%
Day's Open 132.47
Day's Range 128.90 - 135.87
Day's Volume 9,865,757
52-Week Range 18.23 - 169.86


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 23 hours ago

Three especially stand out.

The Motley Fool - 1 day ago

The success of Moderna's COVID-19 vaccine could be just the beginning.

The Motley Fool - 2 days ago

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Other stocks mentioned: AZN, BAC, BNTX, JNJ, PFE
CNBC - 2 days ago

The CDC says the two products are not interchangeable, but it added in updated guidance posted Thursday that it's OK to mix the shots in rare circumstances.

Other stocks mentioned: BNTX, PFE
Forbes - 2 days ago

Only 0.03% of Moderna shots administered through Jan. 10 resulted in a reported “adverse event.”

Zacks Investment Research - 2 days ago

Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.

Business Insider - 3 days ago

Moderna surged as much as 9% on Thursday on news California has reauthorized a batch of the company's vaccine following an allergy scare.  Earlier this week, the state urged a pause on the use...

The Motley Fool - 3 days ago

Developments on both sides of the Pacific Ocean seem to be driving the stock northward.

Business Wire - 3 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces first participant dosed in Phase 1/2 study of Moderna COVID-19 Vaccine in Japan led by Takeda.

Benzinga - 4 days ago

Inoculation with Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine in California can resume after the state said it was safe to use the batch of the vaccine that was linked to adverse events in so...

Bloomberg Technology - 4 days ago

Moderna's Chairman on Biden's COVID-19 Vaccine Promise

Jan.20 -- Moderna Co-Founder and Chairman Noubar Afeyan discusses President Biden's COVID-19 vaccine distribution plan and its chances of success. He also talks about the shortcomings of the i...

Zacks Investment Research - 4 days ago

Moderna (MRNA) closed the most recent trading day at $125.14, moving +0.1% from the previous trading session.

InvestorPlace - 4 days ago

Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making t...

Other stocks mentioned: AZN, BNTX, JNJ, NVAX, PFE
Forbes - 4 days ago

Moderna stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the g...

The Motley Fool - 4 days ago

A small number of people at one location in California experienced such effects after being inoculated with mRNA-1273.

Investopedia - 5 days ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: BIIB, BIO, CVS, HZNP, PODD, QDEL, TDOC
The Motley Fool - 5 days ago

We just have to wait to find out if he's right.

Forbes - 6 days ago

The vaccine batch was temporarily paused “out of an extreme abundance of caution” after fewer than 10 people had a severe reaction.

The Motley Fool - 1 week ago

The company avoided a much-dreaded scenario.

The Motley Fool - 1 week ago

Here's where to invest your money right now.

Other stocks mentioned: AMD, DIS, LMND, SQ
The Motley Fool - 1 week ago

Two mRNA COVID vaccines aced clinical trials. Now new virus variants are putting them to the test.

Other stocks mentioned: PFE
The Motley Fool - 1 week ago

Its coronavirus vaccine isn't the only cause of investor celebration.

InvestorPlace - 1 week ago

The wild volatility in Moderna stock before and after its vaccine approval is coming to an end but its long-term prospects are on the way up. The post Why Moderna Has More Upside Than Its Covi...

Investors Business Daily - 1 week ago

Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride.

The Motley Fool - 1 week ago

Both of these biotechs could be big winners in the COVID-19 vaccine market.

Other stocks mentioned: NVAX
Seeking Alpha - 1 week ago

Over the past three months MRNA insiders have cashed out of the stock. A restriction on insider sales for certain executives was lifted in late December. This could exacerbate insider sales.

The Motley Fool - 1 week ago

The company wants to see if it can still produce a sufficient response one year after inoculation.

Benzinga - 1 week ago

Moderna Inc. (NASDAQ: MRNA) is planning to test the efficacy of COVID-19 vaccine booster shots a year after initial doses of the vaccine have been administered to an individual, CNBC reported ...

CNBC Television - 1 week ago

Moderna plans to test booster shot for Covid-19 vaccine trial patients

CNBC's Meg Tirrell reports on Moderna's plan to test the longevity of its Covid vaccine.

CNBC - 1 week ago

Moderna is planning to test a booster shot of its Covid-19 vaccine one year after initial vaccination, as duration of protection isn't yet known.

Seeking Alpha - 1 week ago

Year 2020 was wild, and left many important threats for 2021. I will summarize the key threats I see, and offer my approach to the markets.

Other stocks mentioned: AWR, CLX, CVX, DTE, ENB, HD, JNJ, MO, PFE, T, V, XLE
The Motley Fool - 1 week ago

Their winning streaks aren't over just yet.

Other stocks mentioned: TDOC
Zacks Investment Research - 1 week ago

Moderna (MRNA) closed at $124.06 in the latest trading session, marking a -0.39% move from the prior day.

CNBC - 1 week ago

"We are going to live with this virus, we think, forever," he said during a panel discussion at the JPMorgan Healthcare Conference.

InvestorPlace - 1 week ago

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

Other stocks mentioned: ABBV, BMY, ELAN, JAZZ, JNJ, PFE
InvestorPlace - 1 week ago

In a market rife with speculation, the best speculation may be targeting value. The post 7 Great Speculations for 2021 appeared first on InvestorPlace.

Other stocks mentioned: F, BABA, DKNG, GE, INTC, PLUG
Benzinga - 1 week ago

Uber Inc (NYSE: UBER) and Moderna Inc (NASDAQ: MRNA) said they are collaborating on supporting the uptake of COVID-19 vaccines. What Happened: The two companies will initially work on providin...

Other stocks mentioned: UBER
The Motley Fool - 1 week ago

The biotech promises that more collaborations are coming.

Other stocks mentioned: UBER
The Motley Fool - 1 week ago

A coronavirus vaccine authorization, a new partnership, and a bullish revenue forecast have investors excited.

Seeking Alpha - 1 week ago

Moderna's vaccine delay is hardly fault of its own. The bigger investment picture becomes visible when you ignore the small setbacks and concentrate on the larger factors - in this case, mRNA-...

Zacks Investment Research - 1 week ago

COVID-19 Vaccine Production to Ramp Up

Other stocks mentioned: BNTX, PFE
Zacks Investment Research - 1 week ago

Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.

Forbes - 1 week ago

Moderna (NASDAQ: MRNA) stock rose by about 4% over the last week to levels of around $113 per share. Here's a quick rundown of the developments for the company over the last week.

Benzinga - 1 week ago

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate mRNA-1273 gained another regulatory approval Tuesday.  Separately, the company also announced a high-profile executive appointment.

TechCrunch - 1 week ago

Uber and pharmaceutical company Moderna have announced a partnership around COVID-19 vaccination, which will include a number of different initiatives. To start, it's only confirmed component ...

Other stocks mentioned: UBER
Market Watch - 1 week ago

Shares of Moderna Inc. were up 0.8% in premarket trading on Tuesday after the company said its COVID-19 vaccine has been authorized in Switzerland. The country has also agreed to purchase 7.5 ...

Market Watch - 1 week ago

Uber Technologies Inc. and Moderna Inc. said Tuesday they will collaborate to explore ways to support the uptake of COVID-19 vaccines. The ridesharing and delivery company and the biotech said...

Other stocks mentioned: UBER
Business Wire - 1 week ago

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Uber Technologies, Inc. (NYSE:...

Other stocks mentioned: UBER
Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--José M. Vega, M.D. joins Moderna as Chief Safety Officer.

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss A...

About MRNA

Moderna, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has str... [Read more...]

IPO Date
Dec 7, 2018
Stephane Bancel
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, Moderna's revenue was $60.21 million, a decrease of -55.42% compared to the previous year's $135.07 million. Losses were -$514.02 million, 33.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 144.38, which is an increase of 10.20% from the latest price.

Price Target
(10.20% upside)
Analyst Consensus: Buy